Literature DB >> 12077191

Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.

Stephane Palfi1, Liza Leventhal, Yaping Chu, Shuang Y Ma, Marina Emborg, Roy Bakay, Nicole Déglon, Philippe Hantraye, Patrick Aebischer, Jeffrey H Kordower.   

Abstract

The primate striatum contains tyrosine hydroxylase (TH)-immunoreactive (ir) neurons, the numbers of which are augmented after dopamine depletion. Glial cell line-derived neurotrophic factor (GDNF) strongly modulates the viability and phenotypic expression of dopamine ventral mesencephalic neurons. The effect of GDNF on TH-ir neurons intrinsic to the striatum has yet to be investigated. In the present study, stereological counts of TH-ir striatal neurons in aged and parkinsonian nonhuman primates revealed that GDNF delivered via a lentiviral vector (lenti-) further increased the number of these cells. Aged monkeys treated with lenti-GDNF displayed an eightfold increase in TH-ir neurons relative to lenti-beta-galactosidase-treated monkeys. Unilateral 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine treatment alone in young monkeys resulted in a bilateral eightfold increase in TH-ir striatal cells. This effect was further magnified sevenfold on the side of lenti-GDNF treatment. These cells colocalized with the neuronal marker neuronal-specific nuclear protein. Some of these cells colocalized with GDNF-ir, indicating that an alteration in phenotype may occur by the direct actions of this trophic factor. Thus, GDNF may mediate plasticity in the dopamine-depleted primate brain, which may serve to compensate for cell loss by converting striatal neurons to a dopaminergic phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077191      PMCID: PMC6757756     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  26 in total

1.  Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.

Authors:  P A Lapchak; P J Miller; F Collins; S Jiao
Journal:  Neuroscience       Date:  1997-05       Impact factor: 3.590

2.  Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS.

Authors:  M Trupp; N Belluardo; H Funakoshi; C F Ibáñez
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

Review 3.  Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach.

Authors:  E Bezard; C E Gross
Journal:  Prog Neurobiol       Date:  1998-06       Impact factor: 11.685

4.  Dopaminergic neurons protected from degeneration by GDNF gene therapy.

Authors:  D L Choi-Lundberg; Q Lin; Y N Chang; Y L Chiang; C M Hay; H Mohajeri; B L Davidson; M C Bohn
Journal:  Science       Date:  1997-02-07       Impact factor: 47.728

5.  Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease.

Authors:  N Déglon; J L Tseng; J C Bensadoun; A D Zurn; Y Arsenijevic; L Pereira de Almeida; R Zufferey; D Trono; P Aebischer
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

6.  Primate neostriatal neurons containing tyrosine hydroxylase: immunohistochemical evidence.

Authors:  M Dubach; R Schmidt; D Kunkel; D M Bowden; R Martin; D C German
Journal:  Neurosci Lett       Date:  1987-03-31       Impact factor: 3.046

7.  Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia.

Authors:  A Carlsson; B Winblad
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

8.  Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons.

Authors:  X Du; N D Stull; L Iacovitti
Journal:  Brain Res       Date:  1995-05-22       Impact factor: 3.252

Review 9.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

Review 10.  Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature.

Authors:  R Adolfsson; C G Gottfries; B E Roos; B Winblad
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

View more
  43 in total

Review 1.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 2.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

3.  Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.

Authors:  A M Fletcher; T H Kowalczyk; L Padegimas; M J Cooper; D M Yurek
Journal:  Neuroscience       Date:  2011-08-04       Impact factor: 3.590

Review 4.  Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.

Authors:  Ronald J Mandel; Corinna Burger; Richard O Snyder
Journal:  Exp Neurol       Date:  2007-08-24       Impact factor: 5.330

5.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

6.  Long-term transgene expression in mouse neural progenitor cells modified with phiC31 integrase.

Authors:  Annahita Keravala; Brandi K Ormerod; Theo D Palmer; Michele P Calos
Journal:  J Neurosci Methods       Date:  2008-06-17       Impact factor: 2.390

7.  Anatomical and electrophysiological changes in striatal TH interneurons after loss of the nigrostriatal dopaminergic pathway.

Authors:  Bengi Ünal; Fulva Shah; Janish Kothari; James M Tepper
Journal:  Brain Struct Funct       Date:  2013-10-31       Impact factor: 3.270

Review 8.  Gene-based therapies in Parkinson's disease.

Authors:  Patricia J Allen; Andrew Feigin
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

9.  Are striatal tyrosine hydroxylase interneurons dopaminergic?

Authors:  Harry S Xenias; Osvaldo Ibáñez-Sandoval; Tibor Koós; James M Tepper
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

Review 10.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.